


TSE : 4568

# Reference Data

(Consolidated Financial Results for Q3 FY2009)



**Daiichi-Sankyo**

January 29, 2010

Corporate Communications Department  
<http://www.daiichisankyo.com>

(This page is intentionally left blank)



**DAIICHI SANKYO CO., LTD.**



Daiichi-Sankyo

TSE : 4568

# Reference Data

(Consolidated Financial Results for Q3 FY2009)

[1] Summary of Income Statement	P1,2
[2] Currency Rate	P3
[3] Sales of Global Products	P3
[4] Overseas Sales	P4
[5] Consolidated Segment Information – Operating Segment	P5
[6] Consolidated Segment Information – Geographic Segment	P5
[7] Status of Major Companies	P6~9
[8] Number of Employees	P10
[9] Consolidated Balance Sheets	P11,12
[10] Consolidated Statements of Cash Flows	P13
[11] R&D Pipeline	P14,15

<Historical Data>

Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk and uncertainty. For this reason, the actual performance data, etc. may differ from the prospective value.

# 1. Summary of Income Statement

< Daiichi Sankyo Group - Consolidated >

(Billions of yen)

	FY2009 Results					Details (YoY Changes)		
	Q3	Progress of 2nd half Forecast (Jan.)		YoY Changes	Q3 YTD			
Net Sales	<15.3>				<15.6>			- Consolidation of Ranbaxy: +102.2 - Azor (lump sum payment received) in FY2008: -4.7 - Decrease by yen appreciation: -24.0 \$ ⇒ -16.0 € ⇒ -8.0 - Increase of Olmesartan sales: +17.9 - Decrease of Levofloxacin sales: -9.7 [Underlined figures include loss from currency fluctuation]
Cost of Sales	29.6	75.4	51.0%	22.3	29.3	212.7	61.9	- Cost to sales ratio: +5.3 Points Impact of consolidation of Ranbaxy: +4.4 Points Impact of currency fluctuation: +0.7 Points
SG&A expenses	55.1	140.5	47.4%	8.7	58.3	422.9	44.2	
R&D expenses	18.7	47.6	47.6%	0.7	19.5	141.7	12.5	- Consolidation of Ranbaxy: +6.8 - Increase in development costs of Edoxaban (DU-176b), etc.
Other expenses	36.4	92.9	47.2%	8.0	38.8	281.2	31.6	- Consolidation of Ranbaxy: +38.8
Operating income	<7.6>				<-8.2>			
	15.4	39.2	86.8%	2.8	12.4	90.1	-8.0	
Non-operating income		4.3	30.1%	1.2		19.1	9.9	- Gain on valuation of Ranbaxy's USD / INR forex derivatives
Non-operating expenses		5.1	44.0%	-0.8		18.5	4.5	- Loss realized due to arrival of forex derivative due date
Ordinary income	<14.4>				<-2.7>			
	15.0	38.4	80.4%	4.8	12.5	90.6	-2.5	
Extraordinary gains		1.5	56.1%	-0.3		3.8	1.2	- Gain on sales of investment securities: +1.8
Extraordinary losses		2.5	31.8%	-354.8		3.5	-357.8	- Absence of 354.0 bill of amortization of goodwill (following acquisition of Ranbaxy's shares) a year ago
Income before income taxes and minority interests	14.6	37.3	88.1%	359.3	12.5	91.0	356.4	
Net Income	< - >				< - >			- Income taxes: 52.8 (Tax rate 58.0%) [Factors leading to increase in tax rate] Amendment of income taxes for the previous year: 7.5 Non-application of R&D tax credits on parent - Minority interests in loss: -1.0
	8.1	20.6	78.1%	352.4	5.4	39.2	337.1	

< Ranbaxy >

(Billions of yen)

	FY2009 Results			
	Q3		Q3 YTD	
Net Sales	< - >		< - >	
	100.0	36.0	100.0	102.2
Cost of Sales	55.0	19.8	56.2	57.4
SG&A expenses	40.6	14.6	44.6	45.6
R&D expenses	6.6	2.4	6.7	6.8
Other expenses	34.0	12.2	38.0	38.8
Operating income	< - >		< - >	
	4.4	1.6	-0.8	-0.8
Non-operating income		2.5		12.4
Non-operating expenses		2.9		13.8
Ordinary income	< - >		< - >	
	3.2	1.2	-2.1	-2.1
Extraordinary gains		0.0		0.0
Extraordinary losses		0.0		0.0
Income before income taxes and minority interests	3.2	1.1	-2.1	-2.1
Net Income	< - >		< - >	
	-0.6	-0.2	-2.9	-2.9

< Impact of Business Combination of Ranbaxy >

(Billions of yen)

	FY2009 Results			
	Q3	YoY Changes	Q3 YTD	YoY Change
Net Sales				
Cost of Sales				
SG&A expenses	1.5	-4.0	4.5	-1.0
R&D expenses	1.5	-4.0	4.5	-1.0
Operating income	-1.5	4.0	-4.5	1.0
Non-operating income				
Non-operating expenses				
Ordinary income	-1.5	4.0	-4.5	1.0
Extraordinary gains				
Extraordinary losses	0.0	-354.0	0.0	-354.0
Income before income taxes and minority interests	-1.5	358.0	-4.5	355.0
Net Income	0.8	360.3	-1.0	358.5

(Billions of yen)

	FY2009 Forecast							Details (From Forecast)
	2nd half		YoY Changes	Full Year		YoY Changes	From Oct. Forecast	
Net Sales	<12.3>			<14.0>				Positive: Overseas subsidiaries contribution to sales Negative: Downward amendment of domestic prescription drugs
	100.0	489.4	53.6	100.0	960.0	117.9	0.0	
Cost of Sales	30.2	147.8	31.0	29.7	285.0	70.6	2.0	- Change in business mix
SG&A expenses	60.6	296.5	4.7	60.3	579.0	40.1	-2.0	- Ongoing structural improvements
R&D expenses	20.4	99.9	-2.3	20.2	194.0	9.5	0.0	
Other expenses	40.2	196.6	7.0	40.1	385.0	30.7	-2.0	
Operating income	<65.6>			<8.0>				
	9.2	45.1	17.9	10.0	96.0	7.1	0.0	
Non-operating income		14.2	8.0		29.0	16.7	23.0	- Improvements in Ranbaxy's valuation gain/loss on derivatives due to rupee appreciation against US dollar October forecast based on forex rate at end-Mar 2009 Revised forecast based on forex rate at end-Dec 2009
Non-operating expenses		11.6	-26.3		25.0	-21.0	-8.0	- Loss realized due to arrival of forex derivative due date
Ordinary income	<- - >			<81.3>				
	9.8	47.7	52.2	10.4	100.0	44.8	31.0	
Extraordinary gains		2.6	-0.3		5.0	1.2	2.6	
Extraordinary losses		8.0	-355.3		9.0	-358.2	6.6	- Increase in costs related to transfer of Shizuoka Plant and reorganization of Asubio Pharma
Income before income taxes and minority interests	8.7	42.3	407.2	10.0	96.0	404.3	27.0	
Net Income	<- - >			<- - >				- Modest increase in net income due to more income tax adjustment, reflecting amended tax calculation for previous fiscal year and non-application of R&D tax credits
	5.4	26.3	275.8	4.7	45.0	260.5	5.0	

## &lt; Daiichi Sankyo's Performance excluding the impact of Ranbaxy's Consolidation &gt;

(Billions of yen)

	FY2009 Results					
	Q3		YoY Changes	Q3 YTD		YoY Changes
Net Sales	<-1.0>			<-0.7>		
	100.0	219.1	-2.2	100.0	623.5	-4.1
Cost of Sales	25.4	55.6	2.4	24.9	155.3	4.5
SG&A expenses	56.8	124.3	-1.9	59.8	372.8	-0.5
R&D expenses	20.6	45.2	-1.6	21.6	134.9	5.7
Other expenses	36.1	79.1	-0.2	38.2	237.9	-6.2
Operating income	<-6.7>			<-7.9>		
	17.9	39.1	-2.8	15.3	95.4	-8.2
Non-operating income		1.8	-1.3		6.7	-2.5
Non-operating expenses		2.2	-3.8		4.7	-9.3
Ordinary income	<-0.8>			<-1.4>		
	17.7	38.7	-0.3	15.6	97.3	-1.4
Extraordinary gains		1.5	-0.4		3.8	1.1
Extraordinary losses		2.5	-0.8		3.5	-3.8
Income before income taxes and minority interests	17.2	37.7	0.2	15.7	97.6	3.5
Net Income	<-27.9>			<-30.1>		
	9.1	20.0	-7.7	6.9	43.1	-18.5

## 2. Currency Rate

	FY2008	FY2009				FY2009 Original Forecast	
	Q3 YTD Results	Q3 YTD Results	Q4 Forecast	Full Year Forecast	Annual impact of one yen change in currency rate		Full Year
USD / Yen (average)	102.8	93.5	90.0	92.6	Net Sales Operating Income	¥2.3 billion ¥0.3 billion	95.0
EUR / Yen (average)	150.7	133.0	130.0	132.2	Net Sales Operating Income	¥0.6 billion -	120.0

## 3. Sales of Global Products

(Billions of yen)

	FY2009 Results					FY2009 Forecast			
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
<b>Olmesartan</b> <antihypertensive>	<b>&lt;12.3&gt;</b>			<b>&lt;11.0&gt;</b>		<b>&lt;15.1&gt;</b>	<b>&lt;12.7&gt;</b>		
	<b>64.7</b>	<b>52.7%</b>	<b>7.1</b>	<b>180.1</b>	<b>17.9</b>	<b>122.6</b>	<b>238.0</b>	<b>-2.0</b>	<b>26.9</b>
Olmetec (JPN)	<18.8>			<22.1>		<18.4>	<21.2>		
	22.2	56.6%	3.5	61.0	11.1	39.2	78.0	-4.0	13.6
Benicar HCT / Benicar (US)	<2.0>			<-1.1>		<4.3>	<0.7>		
	22.7	52.0%	0.4	67.0	-0.7	43.7	88.0	2.0	0.6
Azor (US)	<38.6>			<53.4>		<39.1>	<49.8>		
	3.6	53.6%	1.0	9.8	3.4	6.8	13.0	0.0	4.3
Olmetec Plus / Olmetec (EU)	<12.1>			<2.5>		<20.7>	<9.3>		
	10.2	45.0%	1.1	28.5	0.7	22.8	41.0	0.0	3.5
Sevikar (EU)	<56.5>			<208.1>		<55.0>	<151.3>		
	2.2	64.1%	0.8	4.3	2.9	3.4	5.5	0.0	3.3
Other subsidiaries / Export, etc.	<6.2>			<6.3>		<20.4>	<13.4>		
	3.7	54.2%	0.2	9.4	0.6	6.8	12.5	0.0	1.5
<b>Levofloxacin</b> <synthetic antibacterial>	<b>&lt;-14.2&gt;</b>			<b>&lt;-12.9&gt;</b>		<b>&lt;-14.8&gt;</b>	<b>&lt;-13.5&gt;</b>		
	<b>22.1</b>	<b>53.6%</b>	<b>-3.7</b>	<b>65.4</b>	<b>-9.7</b>	<b>41.2</b>	<b>84.5</b>	<b>-4.0</b>	<b>-13.2</b>
Cravitt (JPN)	<-21.0>			<-3.2>		<-20.6>	<-7.0>		
	10.8	58.4%	-2.9	32.3	-1.1	18.6	40.0	-4.0	-3.0
Export, etc	<-17.6>			<-32.1>		<-14.7>	<-27.6>		
	5.1	44.9%	-1.1	16.3	-7.7	11.3	22.5	0.0	-8.6
Royalty	<0.7>			<-9.5>		<-5.0>	<-9.8>		
	4.1	53.6%	0.0	11.0	-1.1	7.6	14.5	0.0	-1.6
Other subsidiaries	<14.7>			<3.6>		<1.4>	<-0.2>		
	2.1	56.8%	0.3	5.9	0.2	3.7	7.5	0.0	0.0
<b>Pravastatin</b> <antihyperlipidemic>	<b>&lt;-10.8&gt;</b>			<b>&lt;-8.2&gt;</b>		<b>&lt;-9.1&gt;</b>	<b>&lt;-7.9&gt;</b>		
	<b>14.8</b>	<b>56.4%</b>	<b>-1.8</b>	<b>44.5</b>	<b>-4.0</b>	<b>26.3</b>	<b>56.0</b>	<b>0.0</b>	<b>-4.8</b>
Mevalotin (JPN)	<-9.1>			<-7.5>		<-8.1>	<-7.3>		
	12.8	57.9%	-1.3	37.7	-3.1	22.1	47.0	0.0	-3.7
Export, etc	<-39.8>			<-19.0>		<-34.1>	<-21.3>		
	0.4	42.8%	-0.3	2.0	-0.5	0.9	2.5	0.0	-0.7
European Subsidiaries	<-37.7>			<-25.2>		<-31.4>	<-24.4>		
	0.8	56.6%	-0.5	2.4	-0.8	1.4	3.0	0.0	-1.0
Other subsidiaries	<37.8>			<16.4>		<28.2>	<17.9>		
	0.8	43.7%	0.2	2.5	0.3	1.9	3.5	0.0	0.5
<b>Prasugrel (alliance revenue)</b> <antiplatelet>	<b>&lt;&gt;</b>			<b>&lt;&gt;</b>					
	<b>0.3</b>	<b>-</b>	<b>0.3</b>	<b>1.2</b>	<b>1.2</b>				
Effient (US)	<>			<>					
	0.2	-	0.2	1.1	1.1				
Effient (EU)	<>			<>					
	0.1	-	0.1	0.1	0.1				

Forecast of prasugrel is not disclosed.

## 4. Overseas Sales

Consolidated basis

	FY2009 Results				
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes
Overseas sales	<43.9> <b>120.6</b>	<b>47.2%</b>	<b>36.8</b>	<36.6> <b>353.2</b>	<b>94.6</b>
Overseas sales ratio	<b>47.3%</b>			<b>48.7%</b>	
North America	<11.5> 58.9	-	6.1	<9.5> 180.3	15.6
Europe	<32.9> 29.2	-	7.2	<27.2> 86.1	18.4
Other	<259.4> 32.5	-	23.5	<231.3> 86.8	60.6

(Billions of yen)

FY2009 Forecast			
2nd half	Full Year	From Oct. Forecast	YoY Changes
<28.7> <b>255.4</b>	<30.7> <b>488.0</b>	<b>19.0</b>	<b>114.7</b>
<b>52.2%</b>	<b>50.8%</b>		

Overseas sales of Ranbaxy

	FY2009 Results				
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes
Overseas sales	<> <b>35.8</b>	-	<b>35.8</b>	<> <b>101.8</b>	<b>101.8</b>
North America	<> 6.1	-	6.1	<> 21.5	21.5
Europe	<> 6.3	-	6.3	<> 19.3	19.3
Other	<> 23.3	-	23.3	<> 60.9	60.9

Overseas sales excluding Ranbaxy

	FY2009 Results				
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes
Overseas sales	<1.2> <b>84.8</b>	-	<b>1.0</b>	<-2.8> <b>251.4</b>	<b>-7.2</b>
Overseas sales ratio	<b>38.7%</b>			<b>40.3%</b>	
North America	<-0.1> 52.7	-	-0.1	<-3.6> 158.8	-5.9
Europe	<4.1> 22.8	-	0.9	<-1.3> 66.8	-0.9
Other	<1.5> 9.2	-	0.1	<-1.4> 25.8	-0.4

## 5. Consolidated Segment information - Operating Segment

(Billions of yen)

	FY2009 Results					
	Q3		YoY Changes	Q3 YTD		YoY Changes
<b>Net Sales</b>	<b>&lt;15.3&gt;</b>			<b>&lt;15.6&gt;</b>		
		<b>255.1</b>	<b>33.8</b>		<b>725.7</b>	<b>98.0</b>
Pharmaceuticals	<15.3>	254.4	33.8	<15.7>	723.2	98.1
Domestic	<-2.0>	120.7	-2.5	<1.8>	334.0	5.8
Overseas	<44.5>	121.3	37.4	<36.8>	353.5	95.0
OTC drugs	<-8.2>	12.1	-1.1	<-5.6>	35.1	-2.1
Other	<-4.4>	0.7	0.0	<-3.5>	2.5	-0.1
<b>Operating income</b>	<b>&lt;7.6&gt;</b>			<b>&lt;-8.2&gt;</b>		
		<b>39.2</b>	<b>2.8</b>		<b>90.1</b>	<b>-8.0</b>
Pharmaceuticals	<7.8>	38.7	2.8	<-8.3>	88.4	-8.0
Other	<-3.1>	0.5	0.0	<-1.5>	1.7	0.0

## 6. Consolidated Segment information - Geographic Segment

(Billions of yen)

	FY2009 Results						
	Q3		YoY Changes	Q3 YTD		YoY Changes	
<b>Net Sales</b>	<b>&lt;15.3&gt;</b>			<b>&lt;15.6&gt;</b>			
	<b>100.0</b>	<b>255.1</b>	<b>33.8</b>	<b>100.0</b>	<b>725.7</b>	<b>98.0</b>	
Japan	<-3.3>	57.4	146.4	-5.0	56.5	410.2	-6.8
North America	<15.6>	20.8	53.1	7.2	22.3	161.8	19.9
Europe	<37.8>	9.7	24.8	6.8	9.9	71.8	20.1
India	<->	6.6	16.8	16.8	6.2	44.8	44.8
Other	<136.2>	5.5	13.9	8.0	5.1	37.0	20.0
<b>Operating income</b>	<b>&lt;7.6&gt;</b>			<b>&lt;-8.2&gt;</b>			
		<b>39.2</b>	<b>2.8</b>		<b>90.1</b>	<b>-8.0</b>	
Japan		22.9			50.3		
North America		12.4			39.4		
Europe		3.1			6.2		
India		3.1			-1.8		
Other		2.2			3.5		



## 7. Status of Major Companies

### 7-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2009 Results					FY2009 Forecast			
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
Total net sales of ethical pharmaceuticals	<-1.4>			<2.3>		<-0.3>	<2.0>		
	118.4	57.6%	-1.7	327.8	7.3	205.6	415.0	-15.0	8.3
Cardiovascular disease	<3.0>			<4.9>		<5.6>	<5.8>		
	67.5	55.4%	2.0	191.6	9.0	121.8	246.0	-8.0	13.5
Olmotec <antihypertensive>	<18.8>			<22.1>		<18.4>	<21.2>		
	22.2	56.6%	3.5	61.0	11.1	39.2	78.0	-4.0	13.6
Calblock <antihypertensive>	<12.5>			<15.2>		<14.1>	<15.3>		
	3.8	54.4%	0.4	10.8	1.4	7.0	14.0	-1.0	1.9
Artist <antihypertensive>	<6.0>			<7.8>		<10.4>	<9.5>		
	6.4	52.9%	0.4	18.3	1.3	12.1	24.0	0.0	2.1
Mevalotin <antihyperlipidemic agent>	<-9.1>			<-7.5>		<-8.1>	<-7.3>		
	12.8	57.9%	-1.3	37.7	-3.1	22.1	47.0	0.0	-3.7
Kremezin <treatment for chronic renal failure>	<4.3>			<6.1>		<12.4>	<9.8>		
	3.7	51.5%	0.2	10.5	0.6	7.1	14.0	0.0	1.2
Hanp <treatment for acute cardiac failure>	<-4.8>			<1.6>		<1.8>	<3.6>		
	2.6	52.5%	-0.1	7.1	0.1	5.0	9.5	0.0	0.3
Livalo <antihyperlipidemic agent>	<18.8>			<22.3>		<21.8>	<23.0>		
	2.1	54.1%	0.3	5.7	1.0	3.8	7.5	-1.0	1.4
Sunrythm <antiarrhythmic agent>	<-0.8>			<0.4>		<5.2>	<3.0>		
	3.2	53.2%	0.0	9.2	0.0	6.0	12.0	0.0	0.4
Fastic <antidiabetic agent>	<-0.1>			<2.9>		<10.5>	<7.4>		
	1.4	51.1%	0.0	4.1	0.1	2.8	5.5	-0.5	0.4
Infectious diseases/bone and joint diseases/ immunological allergic diseases/urology	<0.2>			<7.6>		<10.6>	<11.7>		
	44.7	54.2%	0.1	115.6	8.2	82.6	153.5	-1.5	16.0
Cravit <synthetic antibacterial agent>	<-21.0>			<-3.2>		<-20.6>	<-7.0>		
	10.8	58.4%	-2.9	32.3	-1.1	18.6	40.0	-4.0	-3.0
Loxonin <anti-inflammatory analgesic>	<16.0>			<22.0>		<32.7>	<29.2>		
	13.3	50.7%	1.8	37.0	6.7	26.3	50.0	-2.5	11.3
Mobic <anti-inflammatory analgesic>	<-10.6>			<-12.6>		<-7.9>	<-11.0>		
	2.0	55.5%	-0.2	5.9	-0.9	3.5	7.5	-1.5	-0.9
Urief <treatment for dysuria>	<19.3>			<23.7>		<15.1>	<20.1>		
	2.6	50.9%	0.4	7.0	1.3	5.0	9.5	-0.5	1.6
Zyrtec <antiallergic agent>	<8.8>			<13.4>		<1.9>	<7.4>		
	2.4	41.9%	0.2	6.6	0.8	5.8	10.0	0.0	0.7
Contrast agents / cancer / gastric diseases	<-8.7>			<-1.6>		<-1.5>	<0.4>		
	12.7	53.6%	-1.2	38.0	-0.6	23.7	49.0	0.0	0.2
Omnipaque <contrast agent>	<-10.8>			<-3.4>		<-3.0>	<-1.1>		
	7.1	53.6%	-0.9	21.8	-0.8	13.3	28.0	0.0	-0.3
Topotecin <anticancer agent>	<-14.2>			<-1.7>		<3.6>	<4.4>		
	1.5	46.1%	-0.2	4.8	-0.1	3.2	6.5	0.0	0.3

## 7-2. Daiichi Sankyo Healthcare Co., Ltd

(Billions of yen)

	FY2009 Results					FY2009 Forecast			
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
Daiichi Sankyo Healthcare Co., Ltd	<-8.2> 12.1	55.4%	-1.1	<-5.6> 35.1	-2.1	<-6.1> 21.8	<-1.7> 48.0	0.0	0.8
LuLu Series	<-19.5> 2.8	47.3%	-0.7	<-0.4> 8.3	0.0	<-21.9> 6.0	<-17.7> 11.5	0.0	1.7
Gaster 10	<-38.9> 0.6	49.5%	-0.4	<-38.6> 1.6	-1.0	<-26.8> 1.2	<-32.5> 2.2	0.0	-1.1
Shin-Sankyo Ichoyaku series	<2.8> 1.0	52.2%	0.0	<7.7> 2.8	0.2	<12.5> 1.9	<11.6> 3.7	0.0	0.4
Patecs series	<-25.9> 0.5	42.6%	-0.2	<-8.8> 2.1	-0.2	<7.1> 1.2	<2.2> 2.8	0.0	0.1
Transino	<37.4> 0.2	57.4%	0.1	<-54.5> 0.6	-0.8	<24.5> 0.4	<-48.2> 0.8	0.0	-0.7

## 7-3. Daiichi Sankyo, Inc. (US)

(Billions of yen)

	FY2009 Results					FY2009 Forecast			
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes
Daiichi Sankyo, Inc. (DSI)	<5.8> 34.4	51.0%	1.9	<-0.5> 100.9	-0.5	<11.7> 67.5	<-3.6> 134.0	0.0	4.7
mil USD	<13.4> 382	51.0%	45	<9.4> 1,079	93	<17.7> 749	<12.4> 1,446	1	160
Benicar / Benicar HCT <antihypertensive>	<2.0> 22.7	52.0%	0.4	<-1.1> 67.0	-0.7	<4.3> 43.7	<-0.7> 88.0	2.0	0.6
mil USD	<9.7> 253	52.0%	22	<8.7> 716	57	<10.3> 486	<-9.2> 950	22	80
Azor <antihypertensive>	<38.6> 3.6	53.6%	1.0	<53.4> 9.8	3.4	<39.1> 6.8	<-49.8> 13.0	0.0	4.3
mil USD	<50.9> 40	53.5%	14	<68.6> 105	43	<48.9> 75	<-62.5> 140	0	54
Welchol <antihyperlipidemic / type 2 diabetes>	<10.2> 7.3	53.7%	0.7	<8.0> 20.7	1.5	<13.8> 13.6	<10.2> 27.0	0.0	2.5
mil USD	<18.7> 81	53.6%	13	<18.7> 221	35	<20.4> 151	<-19.6> 291	0	48
Effient (alliance revenue) <antiplatelet>	<> 0.2	-	0.2	<> 1.1	1.1	<> <>	<> <>	<> <>	<> <>
mil USD	<> 2	-	2	<> 12	12	<> <>	<> <>	<> <>	<> <>

Forecast of Effient is not disclosed.

## 7-4. Luitpold Pharmaceuticals, Inc. (US)

	FY2009 Results						FY2009 Forecast			
	Q3		Progress	YoY Changes	Q3 YTD		2nd half	Full Year	From Oct. Forecast	YoY Changes
Luitpold Pharmaceuticals, Inc. (LPI)	<-6.4>				<-2.6>		<-2.3>	<-0.7>		
	12.6	51.0%	-0.9	39.4	-1.1	24.6	51.5	2.5	0.4	
mil USD	<1.1>			<7.0>		<8.2>	<-9.3>			
	140	51.0%	1	421	28	275	556	27	47	
Venofer <treatment for iron deficiency anemia>	<-4.1>			<-4.2>		<-2.1>	<-3.3>			
	8.0	53.7%	-0.3	24.1	-1.1	14.9	31.0	0.0	-1.0	
mil USD	<3.3>			<5.3>		<3.5>	<5.0>			
	89	53.7%	3	258	13	165	334	0	16	

## 7-5. Daiichi Sankyo Europe GmbH

	FY2009 Results						FY2009 Forecast			
	Q3		Progress	YoY Changes	Q3 YTD		2nd half	Full Year	From Oct. Forecast	YoY Changes
Daiichi Sankyo Europe GmbH (DSE)	<6.1>				<6.1>		<12.7>	<-9.6>		
	19.1	46.3%	1.1	54.8	3.2	41.3	77.0	0.0	6.7	
mil €	<5.9>			<20.2>		<11.0>	<18.9>			
	144	45.8%	8	412	69	314	582	-3	92	
Olmetec / Olmetec Plus <antihypertensive>	<12.1>			<2.5>		<20.7>	<-9.3>			
	10.2	45.0%	1.1	28.5	0.7	22.8	41.0	0.0	3.5	
mil €	<10.6>			<16.2>		<17.9>	<18.6>			
	77	44.6%	7	214	30	173	310	-2	49	
Sevikar <antihypertensive>	<56.5>			<208.1>		<55.0>	<151.3>			
	2.2	64.1%	0.8	4.3	2.9	3.4	5.5	0.0	3.3	
mil €	<77.6>			<249.2>		<68.9>	<172.7>			
	16	63.6%	7	32	23	26	42	0	26	
Mevalotin <antihyperlipidemic agent>	<-37.7>			<-25.2>		<-31.4>	<-24.4>			
	0.8	56.6%	-0.5	2.4	-0.8	1.4	3.0	0.0	-1.0	
mil €	<-36.7>			<-15.2>		<-32.8>	<-18.0>			
	6	56.0%	-3	18	-3	10	23	0	-5	
Evista <treatment for osteoporosis>	<-31.1>			<-27.8>		<-4.0>	<-16.6>			
	2.1	41.7%	-0.9	7.1	-2.7	5.0	10.0	0.0	-2.0	
mil €	<-32.8>			<-18.2>		<-9.0>	<-9.5>			
	16	41.3%	-8	53	-12	38	76	0	-8	

### Alliance Revenue of Efient (Europe)

	FY2009 Results			FY2009 Forecast		
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes	
Efient <antiplatelet>	<>			<>		
	0.1	-	0.1	0.1	0.1	
mil USD	<>			<>		
	1	-	1	1	1	

\* Alliance Revenue of Efient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include such revenue.

Forecast of Efient is not disclosed.

## 7-6. Asia, South and Central America (ASCA)

(Billions of yen)

	FY2009 Results					FY2009 Forecast							
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes				
<b>ASCA Total</b>	<b>&lt;11.7&gt;</b>	<b>6.6</b>	<b>49.0%</b>	<b>0.7</b>	<b>&lt;6.6&gt;</b>	<b>18.1</b>	<b>1.1</b>	<b>&lt;13.0&gt;</b>	<b>&lt;8.7&gt;</b>	<b>13.5</b>	<b>25.0</b>	<b>0.0</b>	<b>2.0</b>
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<3.1>	1.1	61.7%	0.0	<2.2>	3.2	0.1	<-7.9>	<-3.1>	1.9	3.9	0.0	-0.1
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	<35.2>	1.4	53.6%	0.4	<40.3>	3.8	1.1	<22.3>	<31.4>	2.7	5.1	0.0	1.2
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<56.8>	0.9	51.4%	0.3	<7.1>	2.5	0.2	<45.4>	<12.9>	1.7	3.4	0.0	0.4
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<4.2>	0.2	38.9%	0.0	<1.0>	0.6	0.0	<31.0>	<15.2>	0.5	0.9	0.0	0.1
Daiichi Sankyo Taiwan Ltd. (DSTW)	<-14.4>	0.7	44.1%	-0.1	<-12.5>	2.4	-0.3	<-1.2>	<-6.9>	1.6	3.2	0.0	-0.2
Daiichi Sankyo Brasil Farmacéutica Ltda. (DSBR)	<-7.2>	1.3	56.8%	-0.1	<-14.1>	3.1	-0.5	<-16.5>	<-17.4>	2.3	4.1	0.0	-0.9
Daiichi Sankyo Venezuela, S.A. (DSVE)	<20.7>	0.8	32.0%	0.1	<32.9>	2.4	0.6	<58.9>	<51.5>	2.7	4.2	0.0	1.4

## 7-7. Ranbaxy Laboratories Limited

(Billions of yen)

	FY2009 Results					
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes	
<b>Ranbaxy Laboratories Limited</b>	<b>&lt;-&gt;</b>	<b>36.0</b>	<b>-</b>	<b>36.0</b>	<b>&lt;102.2&gt;</b>	<b>102.2</b>
bil INR	<->	18.5	-	18.5	<52.4>	52.4

\* Only results are disclosed for Ranbaxy.

## 7-8. ASCA & Ranbaxy's Sales of Global Products

(Billions of yen)

	FY2009 Results					FY2009 Forecast							
	Q3	Progress	YoY Changes	Q3 YTD	YoY Changes	2nd half	Full Year	From Oct. Forecast	YoY Changes				
<b>Olmesartan</b> <antihypertensive>	<b>&lt;22.7&gt;</b>	<b>2.5</b>	<b>59.4%</b>	<b>0.5</b>	<b>&lt;28.6&gt;</b>	<b>6.8</b>	<b>1.5</b>	<b>&lt;3.2&gt;</b>	<b>&lt;15.9&gt;</b>	<b>4.3</b>	<b>8.5</b>	<b>0.0</b>	<b>1.2</b>
<b>Levofloxacin</b> <synthetic antibacterial>	<b>&lt;14.7&gt;</b>	<b>2.1</b>	<b>56.8%</b>	<b>0.3</b>	<b>&lt;3.6&gt;</b>	<b>5.9</b>	<b>0.2</b>	<b>&lt;1.4&gt;</b>	<b>&lt;-0.2&gt;</b>	<b>3.7</b>	<b>7.5</b>	<b>0.0</b>	<b>0.0</b>
<b>Pravastatin</b> <antihyperlipidemic>	<b>&lt;37.8&gt;</b>	<b>0.8</b>	<b>43.7%</b>	<b>0.2</b>	<b>&lt;16.4&gt;</b>	<b>2.5</b>	<b>0.3</b>	<b>&lt;28.2&gt;</b>	<b>&lt;17.9&gt;</b>	<b>1.9</b>	<b>3.5</b>	<b>0.0</b>	<b>0.5</b>

## 8. Number of Employees

	FY2008	FY2009	
	Mar-09	Sep-09	Dec-09*
<b>Total Number of Employees</b>	<b>28,895</b>	<b>29,272</b>	<b>29,467</b>
Japan	9,148	9,323	9,339
Overseas	19,747	19,949	20,128

	FY2008		FY2009			
	Mar-09	MRs	Sep-09	MRs	Dec-09*	MRs
<b>Total Number of Employees</b>	<b>28,895</b>		<b>29,272</b>		<b>29,467</b>	
<b>&lt;Japan&gt;</b>						
Daiichi Sankyo Co., Ltd. (DS)	5,960	2,400	6,042	2,400	6,050	2,400
Daiichi Sankyo Healthcare Co., Ltd (DSHC)	401	150	396	150	394	150
<b>&lt;US&gt;</b>						
Daiichi Sankyo, Inc. (DSI)	2,875	1,800	2,933	1,800	2,927	1,810
Luitpold Pharmaceuticals, Inc. (LPI)	477	70	490	70	488	70
<b>&lt;Europe&gt;</b>						
Daiichi Sankyo Europe GmbH (DSE)	2,436	1,350	2,471	1,360	2,474	1,350
<b>&lt;Asia / Latin America&gt;</b>						
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	459	158	479	175	484	177
Daiichi Sankyo Pharmaceutical (Shanghai) Co., Ltd. (DSSH)	504	208	553	243	559	244
Daiichi Sankyo Hong Kong Ltd. (DSHK)	7	-	7	-	7	-
Daiichi Sankyo Korea Co., Ltd. (DSKR)	98	49	97	49	98	49
Daiichi Sankyo (Thailand) Ltd. (DSTH)	44	18	45	18	49	23
Daiichi Sankyo Taiwan Ltd. (DSTW)	158	69	161	68	163	70
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	292	112	312	117	316	119
Daiichi Sankyo Venezuela, S.A. (DSVE)	131	80	156	86	153	85

	FY2008	FY2009	
	Mar-09	Sep-09	Dec-09*
<b>Ranbaxy Group</b>	<b>12,174</b>	<b>12,127</b>	<b>12,179</b>

\* For overseas subsidiaries with different fiscal year-ends, figures as of Sep-09 are shown

## 9. Consolidated Balance Sheets

<Assets>

(Billions of yen)

	2009.3.31		2009.12.31		Change	Details
		%		%		
<b>Current assets</b>	<b>783.5</b>	<b>52.4%</b>	<b>757.2</b>	<b>52.8%</b>	<b>-26.3</b>	
Cash and time deposits	76.6		78.5		2.0	Liquidity on hand (current deposits + marketable securities + investment securities)
Trade notes and accounts receivable	195.5		230.5		35.0	<u>Total ¥313.1 billion (¥ -51.0 billion from the end of fiscal 2008)</u>
Marketable securities	235.5		208.1		-27.4	Net gain: ¥ +39.2 billion Dividends paid: ¥ -49.3 billion Repayment of bank loans by Daiichi Sankyo and Ranbaxy Acquisition of PharmaForce by LPI
Inventories	139.5		142.3		2.9	Breakdown of inventories as of Dec-2009: Merchandise and finished goods <u>¥ 93.5 billion</u> Work in process: <u>¥ 15.4 billion</u> Raw materials and supplies: <u>¥ 33.5 billion</u>
Deferred tax assets	76.7		57.8		-19.0	Shift from non-current deferred tax assets <u>¥ +13.8 billion</u> Reversal of deferred tax assets <u>¥ -26.5 billion</u> , consisting of Amount equivalent to tax for taxable income of FY2009 and Amendment of income taxes for the previous year
Other current assets	60.8		41.1		-19.6	Refund of income taxes paid in FY2008
Allowance for doubtful accounts	-1.0		-1.1		-0.1	
<b>Non-current assets</b>	<b>711.1</b>	<b>47.6%</b>	<b>676.4</b>	<b>47.2%</b>	<b>-34.7</b>	
Property, plant and equipment	250.1	16.7%	249.0	17.4%	-1.1	
Buildings and structures	132.7		128.6		-4.1	
Machinery, equipment and vehicles	46.0		44.5		-1.5	
Land	42.4		42.5		0.2	
Construction in progress	13.3		19.4		6.1	
Other	15.7		14.0		-1.7	
Intangible assets	192.6	12.9%	189.4	13.2%	-3.2	
Goodwill, net	77.4		85.5		8.2	Amortization: U3 Pharma: <u>¥ -3.8 billion</u> Amortization: Ranbaxy: <u>¥ -1.8 billion</u> Increase from Acquisition of PharmaForce, etc
Other intangible assets, net	115.2		103.8		-11.4	Amortization: Ranbaxy, and sales rights for Evista in EU
Investments and other assets	268.4	18.0%	238.1	16.6%	-30.4	
Investment securities	153.7		140.2		-13.5	
Long-term loans	0.6		0.2		-0.4	
Prepaid pension costs	6.9		4.7		-2.2	
Deferred tax assets	91.6		77.0		-14.6	Shift to current deferred tax assets <u>¥ -13.8 billion</u>
Other assets	15.9		16.2		0.4	
Allowance for doubtful accounts	-0.3		-0.3		0.0	
<b>Total assets</b>	<b>1,494.6</b>	<b>100.0%</b>	<b>1,433.7</b>	<b>100.0%</b>	<b>-60.9</b>	

## &lt;Liabilities and Net Assets&gt;

(Billions of yen)

	2009.3.31		2009.12.31		Change	Details
		%		%		
<b>Liabilities</b>	<b>606.0</b>	<b>40.5%</b>	<b>556.5</b>	<b>38.8%</b>	<b>-49.5</b>	
Current liabilities	508.5	34.0%	253.0	17.6%	-255.5	
Trade notes and accounts payable	59.4		63.4		4.0	
Short-term bank loans	264.3		19.4		-244.9	Change to long-term financing by the issuance of bonds and Long-term bank loans
Income taxes payable	8.2		4.4		-3.8	
Allowance for sales returns	0.6		0.8		0.2	
Allowance for sales rebates	2.7		2.0		-0.7	
Other current liabilities	173.3		163.0		-10.3	
Long-term liabilities	97.4	6.5%	303.5	21.2%	206.0	
Bonds payable	-		100.0		100.0	
Convertible bond-type bonds with subscription rights to shares	47.1		47.6		0.6	
Long-term bank loans	15.9		120.9		105.0	
Deferred tax liabilities	5.4		5.3		-0.1	
Accrued employees' severance and retirement benefits	10.6		11.5		0.9	
Accrued directors' severance and retirement benefits	0.2		0.2		0.0	
Provision for environmental measures	0.1		-		-0.1	
Other long-term liabilities	18.2		17.9		-0.3	
<b>Net assets</b>	<b>888.6</b>	<b>59.5%</b>	<b>877.2</b>	<b>61.2%</b>	<b>-11.5</b>	
Shareholders' equity	894.5	59.8%	884.4	61.7%	-10.0	
Common stock	50.0		50.0		0.0	
Capital surplus	105.2		105.2		0.0	
Retained earnings	753.8		743.8		-10.0	Dividends paid ¥ -49.3 billion Net income ¥ +39.2 billion
Treasury stock at cost	-14.6		-14.6		0.0	
Valuation and other adjustments	-31.4	-2.1%	-33.2	-2.3%	-1.8	
Net unrealized gain on investment securities	19.9		24.4		4.5	
Deferred gains or losses on hedges	0.1		1.0		0.9	
Foreign currency translation adjustments	-51.4		-58.5		-7.2	
Subscription rights to shares	2.4	0.2%	3.0	0.2%	0.6	
Minority interests	23.2	1.6%	22.9	1.6%	-0.3	
<b>Total liabilities and net assets</b>	<b>1,494.6</b>	<b>100.0%</b>	<b>1,433.7</b>	<b>100.0%</b>	<b>-60.9</b>	

## 10. Consolidated Statements of Cash Flows

(Billions of yen)

	FY2008 Q3 YTD	FY2009 Q3 YTD	YoY Change	Details
Income before income taxes and minority interests	-265.4	91.0	356.4	
Depreciation	28.4	33.8	5.4	
Amortization of goodwill	364.6	6.6	-358.0	FY2008: Goodwill write-down on investment in Ranbaxy
(Gain) loss on valuation of derivatives	3.2	-10.5	-13.6	
(Increase) decrease in prepaid pension costs	1.0	2.2	1.2	
(Increase) decrease in trade notes and accounts receivable	-40.0	-35.2	4.8	
(Increase) decrease in inventories	-2.1	-4.0	-1.9	
Increase (decrease) in trade notes and accounts payable	4.4	4.0	-0.4	
Increase (decrease) in accounts payable and accrued expenses	-16.1	-7.3	8.9	
Other, net	0.8	25.6	24.8	FY2009: Refund of income taxes paid in FY2008
Income taxes paid	-51.5	-25.4	26.1	
<b>Cash flows from operating activities</b>	<b>27.1</b>	<b>80.8</b>	<b>53.7</b>	
Net (increase) decrease in short-term operating assets	49.2	100.7	51.5	
(Acquisitions) / proceeds from sales of fixed assets	-30.5	-20.5	10.0	
(Acquisitions) / proceeds from sales of investment securities	-11.0	-0.5	10.5	
Purchases of investments in consolidated subsidiaries	-408.4	-17.8	390.6	FY2008: Acquisition of U3 Pharma and Investment in Ranbaxy FY2009: Acquisition of PharmaForce
Other, net	4.9	0.9	-4.0	
<b>Cash flows from investing activities</b>	<b>-395.8</b>	<b>62.8</b>	<b>458.7</b>	
Net increase (decrease) in short-term bank loans and long-term debt	239.9	-139.5	-379.4	Decrease in short-term bank loans by the issuance of bonds
Proceeds from issuance of bonds	-	99.7	99.7	Issuance of unsecured straight bonds (net of issue cost)
Purchases of treasury stock	-45.8	0.0	45.8	
Dividends paid	-53.3	-49.3	4.0	
Other, net	0.0	-0.2	-0.2	
<b>Cash flows from financing activities</b>	<b>140.8</b>	<b>-89.3</b>	<b>-230.0</b>	
Effect of exchange rate changes on cash and cash equivalents	-10.7	0.7	11.4	
Net increase (decrease) in cash and cash equivalents	-238.7	55.1	293.7	
Cash and cash equivalents, beginning of period	444.3	177.8	-266.6	
Cash and cash equivalents, end of period	205.7	232.8	27.2	



(This page is intentionally left blank)



**DAIICHI SANKYO CO., LTD.**

# 11.Major R&D Pipeline

## Daiichi Sankyo Group Major Research & Development Pipeline (Development Stage)

Therapeutic Area	Main Existing Product	Phase1	Phase2
Cardiovascular diseases	Mevalotin Benicar/Olmetec Azor/Sevikar Welchol Effient/Efient  Olmetec Calblock Artist Mevalotin Kremezin Hanp Livalo Sunrythm Bepricor	DB-772d(US/EU) (oral factor Xa inhibitor)	☆CS-866CMB(JP) (Olmesartan, Hydrochlorothiazide combination)  DU-176b(US/EU) (Edoxaban / VTE / oral factor Xa inhibitor )  CS-747(JP) (Prasugrel / anti-platelet agent)
Glucose metabolic disorders	Welchol  Fastic	CS-1036(JP/Asia) (glucose absorption inhibitor)	
Infectious diseases	Levaquin / Tavanic Banan  Cravit	CS-8958(US/EU) (Laninamivir / anti-influenza / co-development with Biota )	
Cancer	Topotecin Krestin	U3-1287(US) (anti-HER3 antibody)  CS-1008(JP) (Tigatuzumab/anti-DR5 antibody)	CS-1008(US/EU) (Tigatuzumab / anti-DR5 antibody )  CS-7017(US) (PPARγ activator)  DE-766(JP) (Nimotuzumab / anti-EGFR antibody)  ARQ 197(US/EU) (c-Met inhibitor)
Immunological allergic diseases	Zyrtec	CS-0777(US/EU) (immunomodulator)	SUN13834(US) (chymase inhibitor)
Bone/Joint diseases	Loxonin Mobic		
Others	Venofer Evoxac  Omnipaque Omniscan Visipaque Sonazoid Feron Urief		SUN11031(US/EU) (Human ghrelin / cachexia)  ☆DD-723-B(JP) (Perflubutane / ultrasonic contrast agent)


☆Additional indications, new formulations etc.

Change from the announcement in October 2009

# New(underline)

# Change of Stage etc.

CS-866AZ(JP / Approved), CS-8635(EU / Application)

Phase3	Application
<p>★CS-747(US/EU) (Prasugrel / ACS-MM / anti-platelet agent )</p> <p>DU-176b(US/EU/JP/Asia) (Edoxaban / atrial fibrillation / oral factor Xa inhibitor )</p> <p>DU-176b(JP) (Edoxaban / VTE / oral factor Xa inhibitor)</p> 	<p>★CS-866AZ(JP) (Olmesartan, Azelnidipine combination )</p> <p>★CS-8635(US) (Olmesartan, Amlodipine, Hydrochlorothiazide combination )</p> <p>★CS-8635(EU) (Olmesartan, Amlodipine, Hydrochlorothiazide combination )</p>
<p>CS-8958(JP) (Laninamivir / anti-influenza )</p>	<p>★Levofloxacin inj(JP) (new quinolone)</p>
<p>AMG 162(JP) (Denosumab/bone metastases of cancer, osteoporosis / anti-RANKL antibody)</p>	<p>★CS-600G(JP) (Loxoprofen / gel)</p>
<p>SUN11031(JP) (Human ghrelin/anorexia nervosa )</p> <p>SUN Y7017(JP) (Memantine / mild to moderate and severe dementia of Alzheimer type )</p>	<p>KMD-3213(China) (Silodosin / treatment of dysuria associated with benign prostatic hyperplasia)</p>

1. Summary of Income Statement

(Billions of yen)

	FY2008										FY2009							
	Q1		Q2		Q3		Q4		Full Year		Q1	Q2		Q3	Q3 YTD			
Net sales	<-13.5> 100.0	<-2.7> 203.7	<-12.2> 100.0	<-12.2> 221.3	<-16.4> 100.0	<-4.3> 214.5	<-4.3> 100.0	<-4.3> 842.1	<-11.5> 100.0	<-20.2> 227.1	<-15.3> 100.0	<-15.3> 243.4	<-15.3> 100.0	<-15.6> 255.1	<-15.6> 100.0	<-15.6> 725.7		
Cost of sales	23.9	48.6	24.2	49.0	24.0	53.1	29.7	63.6	25.5	214.4	27.5	62.5	30.7	74.7	29.6	75.4	29.3	212.7
Selling, general and administrative expenses	56.5	115.1	65.1	132.0	59.5	131.7	74.6	160.1	64.0	538.9	60.7	137.8	59.4	144.6	55.1	140.5	58.3	422.9
Research and development expenses	18.1	36.9	22.4	45.4	21.2	46.8	25.8	55.4	21.9	184.5	19.9	45.1	20.1	49.0	18.7	47.6	19.5	141.7
Other expenses	38.4	78.2	42.7	86.6	38.4	84.9	48.8	104.7	42.1	354.3	40.8	92.7	39.3	95.6	36.4	92.9	38.8	281.2
Operating income	<-41.0> 19.6	<-17.1> 40.0	<-42.0> 10.7	<-42.0> 21.6	<-42.0> 16.5	<-42.0> 36.4	<-42.0> -	<-42.0> -9.2	<-42.0> 10.6	<-42.0> 88.9	<-33.1> 11.8	<-11.5> 26.8	<-7.6> 9.9	<-7.6> 24.1	<-7.6> 15.4	<-7.6> 39.2	<-7.6> 12.4	<-7.6> 90.1
Non-operating income		3.6		2.5		3.0		3.1		12.3		3.9		10.9		4.3		19.1
Non-operating expenses		2.8		5.3		5.9		31.9		46.0		23.5		-10.1		5.1		18.5
Ordinary income	<-43.0> 20.1	<-35.3> 40.9	<-48.7> 9.3	<-48.7> 18.8	<-48.7> 15.2	<-48.7> 33.5	<-48.7> -	<-48.7> -38.0	<-48.7> 6.6	<-48.7> 55.2	<-82.5> 3.2	<-140.0> 7.2	<-14.4> 18.5	<-14.4> 45.1	<-14.4> 15.0	<-14.4> 38.4	<-14.4> 12.5	<-14.4> 90.6
Extraordinary gains		0.0		0.8		1.8		1.1		3.8		2.1		0.2		1.5		3.8
Extraordinary losses		1.3		2.6		357.4		5.9		367.2		0.7		0.3		2.5		3.5
Income before income taxes and minority interests	19.4	39.5	8.4	17.0	-	-322.0	-	-42.8	-	-308.3	3.8	8.6	18.5	45.0	14.6	37.3	12.5	91.0
Net income	<-39.4> 12.3	<-52.8> 25.1	<-52.8> 4.4	<-52.8> 8.9	<-52.8> -	<-52.8> -331.8	<-52.8> 38.4	<-52.8> 82.3	<-52.8> -	<-52.8> -215.5	<-> -	<-182.7> -6.4	<-> 10.3	<-> 25.1	<-> 8.1	<-> 20.6	<-> 5.4	<-> 39.2

2. Currency Rate

(yen)

	FY2008				FY2009		
	Q1	Q2 YTD	Q3 YTD	Full Year	Q1	Q2 YTD	Q3 YTD
USD / Yen (average)	104.6	106.1	102.8	100.5	97.3	95.5	93.5
EUR / Yen (average)	163.4	162.7	150.7	143.5	132.6	133.2	133.0
INR / Yen (average)	-	-	-	2.00	1.89	1.95	1.95

3. Sales of Global Products

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Olmesartan <antihypertensive>	<-4.5> 50.7	<-23.7> 53.9	<-6.6> 57.6	<-9.1> 49.0	<-8.0> 211.1	<-10.5> 56.0	<-10.2> 59.4	<-12.3> 64.7	<-11.0> 180.1
Olmetec (JPN)	<-12.8> 15.6	<-24.9> 15.7	<-6.0> 18.7	<-28.7> 14.4	<-16.6> 64.4	<-22.1> 19.0	<-26.1> 19.8	<-18.8> 22.2	<-22.1> 61.0
Benicar / Benicar HCT (US)	<-2.6> 23.4	<-1.8> 22.1	<-7.5> 22.3	<-1.6> 19.6	<-0.6> 87.4	<-5.6> 22.1	<-0.5> 22.2	<-2.0> 22.7	<-1.1> 67.0
Azor (US)	<-> 1.4	<-> 2.4	<-39.6> 2.6	<-241.8> 2.3	<-240.7> 8.7	<-121.5> 3.0	<-30.9> 3.2	<-38.6> 3.6	<-53.4> 9.8
Olmetec / Olmetec Plus* (EU)	<-44.3> 8.3	<-40.7> 10.3	<-10.1> 9.1	<-13.6> 9.7	<-10.3> 37.5	<-0.2> 8.3	<-3.7> 10.0	<-12.1> 10.2	<-2.5> 28.5
Sevikar (EU)	<-> -	<-> -	<-> 1.4	<-> 0.8	<-> 2.2	<-> 0.9	<-> 1.2	<-56.5> 2.2	<-208.1> 4.3
Other subsidiaries / Export, etc	<-30.4> 2.0	<-72.2> 3.3	<-62.0> 3.5	<-12.5> 2.2	<-35.6> 11.0	<-29.9> 2.6	<-7.8> 3.1	<-6.2> 3.7	<-6.3> 9.4
Levofloxacin <synthetic antibacterial>	<-12.6> 25.8	<-0.5> 23.6	<-19.8> 25.8	<-4.6> 22.6	<-10.2> 97.7	<-23.2> 19.8	<-0.3> 23.5	<-14.2> 22.1	<-12.9> 65.4
Cravit (JPN)	<-15.5> 10.2	<-6.0> 9.4	<-11.5> 13.7	<-1.2> 9.7	<-9.2> 43.0	<-6.8> 9.5	<-26.7> 11.9	<-21.0> 10.8	<-3.2> 32.3
Export, etc	<-11.3> 9.6	<-19.4> 8.3	<-36.8> 6.2	<-7.6> 7.1	<-8.7> 31.1	<-49.6> 4.8	<-22.7> 6.4	<-17.6> 5.1	<-32.1> 16.3
Royalty	<-12.6> 4.1	<-13.8> 4.0	<-15.9> 4.1	<-26.6> 4.0	<-17.6> 16.1	<-9.9> 3.7	<-19.3> 3.2	<-0.7> 4.1	<-9.5> 11.0
Other subsidiaries	<-1.8> 1.9	<-0.9> 1.9	<-11.9> 1.8	<-2.6> 1.8	<-4.0> 7.5	<-6.4> 1.8	<-2.9> 2.0	<-14.7> 2.1	<-3.6> 5.9
Pravastatin <antihyperlipidemic>	<-25.8> 16.1	<-14.9> 15.9	<-23.3> 16.6	<-15.3> 12.3	<-20.5> 60.8	<-8.5> 14.7	<-5.2> 15.0	<-10.8> 14.8	<-8.2> 44.5
Mevalotin (JPN)	<-17.1> 13.5	<-14.8> 13.1	<-22.6> 14.1	<-14.3> 10.0	<-17.6> 50.7	<-8.3> 12.4	<-5.0> 12.4	<-9.1> 12.8	<-7.5> 37.7
Export	<-39.0> 1.0	<-33.6> 0.8	<-54.0> 0.6	<-3.5> 0.7	<-36.6> 3.2	<-37.6> 0.7	<-23.3> 1.0	<-39.8> 0.4	<-19.0> 2.0
European subsidiaries*	<-74.3> 0.7	<-3.4> 1.2	<-1.2> 1.2	<-43.9> 0.7	<-40.7> 4.0	<-11.3> 0.8	<-34.0> 0.8	<-37.7> 0.8	<-25.2> 2.4
Other subsidiaries	<-3.1> 0.8	<-7.6> 0.8	<-25.4> 0.6	<-7.1> 0.9	<-7.2> 3.0	<-7.7> 0.8	<-8.4> 0.8	<-37.8> 0.8	<-16.4> 2.5

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March. Three months results of Olmetec / Olmetec Plus and Pravastatin from Jan-07 to Mar-07 were ¥6.4 billion(40 million) and ¥1.6 billion (€10 million), respectively.

Prasugrel (alliance revenue) <antiplatelet>				<->	<->	<->	<->	<->	<->
Effient (US)									
Efient (EU)				<->	<->				

## 4. Overseas Sales

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Overseas sales	<-15.9>	<3.6>	<-9.3>	<47.5>	<4.1>	<23.9>	<42.6>	<43.9>	<36.6>
Overseas sales ratio	88.7	86.1	83.8	114.7	373.3	109.8	122.7	120.6	353.2
	43.5%	42.5%	37.9%	53.5%	44.3%	48.4%	50.4%	47.3%	48.7%
North America	<3.9>	<-2.7>	<-15.1>	<21.7>	<0.6>	<1.1>	<16.6>	<11.5>	<9.5>
Europe*	<-42.6>	<31.8>	<12.9>	<37.0>	<-0.3>	<21.3>	<27.6>	<32.9>	<27.2>
Other	<-22.3>	<-10.9>	<-15.4>	<206.7>	<33.6>	<197.4>	<232.9>	<259.4>	<231.3>
	58.3	53.6	52.8	56.6	221.3	58.9	62.5	58.9	180.3
	22.4	23.3	21.9	30.5	98.2	27.2	29.7	29.2	86.1
	8.0	9.2	9.1	27.6	53.8	23.7	30.5	32.5	86.8

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.  
The net sales of DSE for the period from January to March 2007 was ¥14.1 billion.

## 5. Consolidated Segment information - Operating Segment

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Net Sales	<-13.5>	<-2.7>	<-12.2>	<16.4>	<-4.3>	<11.5>	<20.2>	<15.3>	<15.6>
	203.7	202.6	221.3	214.5	842.1	227.1	243.4	255.1	725.7
Pharmaceuticals	<-10.2>	<1.7>	<-8.6>	<21.7>	<-0.2>	<11.5>	<20.3>	<15.3>	<15.7>
Domestic	<-8.2>	<-0.4>	<-9.3>	<1.8>	<-4.7>	<3.1>	<5.0>	<-2.0>	<1.8>
Overseas*	<-14.1>	<5.3>	<-6.1>	<46.7>	<5.9>	<23.9>	<42.5>	<44.5>	<36.8>
OTC drugs	<3.1>	<-5.2>	<-13.2>	<-6.5>	<-6.2>	<6.9>	<-2.1>	<-8.2>	<-5.6>
Other	<-91.5>	<-90.0>	<-93.0>	<-90.7>	<-91.3>	<2.6>	<-3.5>	<-4.4>	<-3.5>
	0.8	1.0	0.8	0.8	3.4	0.8	1.0	0.7	2.5
Operating income	<-41.0>	<-17.1>	<-42.0>	<>	<-43.3>	<-33.1>	<11.5>	<7.6>	<-8.2>
	40.0	21.6	36.4	-9.2	88.9	26.8	24.1	39.2	90.1
Pharmaceuticals	<-42.3>	<-18.9>	<-42.5>	<>	<-44.3>	<-33.5>	<11.9>	<7.8>	<-8.3>
Other	<>	<>	46	-54	<116.2>	<-1.3>	<-0.6>	<-3.1>	<-1.5>
	39.4	20.9	35.9	-9.7	86.6	26.2	23.4	38.7	88.4
	0.5	0.7	0.5	0.5	2.2	0.5	0.7	0.5	1.7

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.  
The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

## 6. Consolidated Segment information - Geographic Segment

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Net Sales	<-13.5>	<-2.7>	<-12.2>	<16.4>	<-4.3>	<11.5>	<20.2>	<15.3>	<15.6>
	203.7	202.6	221.3	214.5	842.1	227.1	243.4	255.1	725.7
Japan	<-12.6>	<-7.3>	<-15.8>	<-8.4>	<-11.4>	<-3.1>	<1.8>	<-3.3>	<-1.6>
North America	<12.5>	<1.4>	<-10.0>	<31.7>	<7.2>	<7.0>	<20.4>	<15.6>	<14.1>
Europe*	<-53.1>	<41.9>	<24.8>	<41.8>	<-0.7>	<48.1>	<32.4>	<37.8>	<38.9>
India	<>	<>	<>	<>	<>	<>	<>	<>	<>
Other	<-16.9>	<-16.3>	<-13.9>	<101.4>	<10.9>	<99.7>	<115.3>	<136.2>	<117.8>
	5.2	5.8	5.9	11.9	28.9	10.5	12.6	13.9	37.0
Operating income	<-41.0>	<-17.1>	<-42.0>	<>	<-43.3>	<-33.1>	<11.5>	<7.6>	<-8.2>
	40.0	21.6	36.4	-9.2	88.9	26.8	24.1	39.2	90.1
Japan	18.5	8.2	25.5	-8.8	43.4	15.6	11.9	22.9	50.3
North America	16.9	10.9	11.6	10.9	50.3	13.9	13.0	12.4	39.4
Europe*	1.2	0.0	0.5	4.0	5.8	1.2	1.9	3.1	6.2
India	-	-	-	-18.9	-18.9	-3.2	-1.7	3.1	-1.8
Other	0.7	0.4	-3.5	2.7	0.4	0.9	0.5	2.2	3.5

\* The accounting period of Daiichi Sankyo Europe GmbH (DSE) was 15 months from January 2007 to March 2008, following a change in its fiscal year-end from December to March.  
The operating results of DSE for the period from January to March 2007 was net sales of ¥14.1 billion and operating income of ¥1.8 billion.

## 7. Status of Major Companies

Data available at [www.daiichisankyo.com/ir/financial/index.html](http://www.daiichisankyo.com/ir/financial/index.html)

### 7-1. Daiichi Sankyo Co., Ltd.

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
<b>Total net sales of ethical pharmaceuticals</b>	<b>&lt;-8.8&gt;</b> <b>100.9</b>	<b>&lt;-0.9&gt;</b> <b>99.5</b>	<b>&lt;-8.9&gt;</b> <b>120.1</b>	<b>&lt;-2.3&gt;</b> <b>86.2</b>	<b>&lt;-4.8&gt;</b> <b>406.7</b>	<b>&lt;-3.7&gt;</b> <b>104.6</b>	<b>&lt;-5.3&gt;</b> <b>104.8</b>	<b>&lt;-1.4&gt;</b> <b>118.4</b>	<b>&lt;-2.3&gt;</b> <b>327.8</b>
<b>Cardiovascular disease</b>	<b>&lt;-5.9&gt;</b> <b>60.0</b>	<b>&lt;-2.2&gt;</b> <b>57.2</b>	<b>&lt;-8.8&gt;</b> <b>65.5</b>	<b>&lt;-0.6&gt;</b> <b>49.9</b>	<b>&lt;-4.8&gt;</b> <b>232.5</b>	<b>&lt;-3.8&gt;</b> <b>62.3</b>	<b>&lt;-8.2&gt;</b> <b>61.9</b>	<b>&lt;-3.0&gt;</b> <b>67.5</b>	<b>&lt;-4.9&gt;</b> <b>191.6</b>
Olmotec <antihypertensive>	<-12.8> 15.6	<-24.9> 15.7	<-6.0> 18.7	<-28.7> 14.4	<-16.6> 64.4	<-22.1> 19.0	<-26.1> 19.8	<-18.8> 22.2	<-22.1> 61.0
Calblock <antihypertensive>	<-19.4> 3.0	<-26.9> 2.9	<-13.6> 3.4	<-17.2> 2.8	<-18.9> 12.1	<-14.5> 3.5	<-18.9> 3.5	<-12.5> 3.8	<-15.2> 10.8
Artist <antihypertensive>	<-3.3> 5.7	<-4.9> 5.3	<-0.5> 6.0	<-6.8> 4.9	<-3.6> 21.9	<-6.3> 6.0	<-11.3> 5.9	<-6.0> 6.4	<-7.8> 18.3
Mevalotin <antihyperlipidemic agent>	<-17.1> 13.5	<-14.8> 13.1	<-22.6> 14.1	<-14.3> 10.0	<-17.6> 50.7	<-8.3> 12.4	<-5.0> 12.4	<-9.1> 12.8	<-7.5> 37.7
Kremezin <treatment for chronic renal failure>	<-3.9> 3.2	<-3.9> 3.2	<-0.5> 3.5	<-5.3> 2.8	<-2.9> 12.8	<-5.5> 3.4	<-8.8> 3.5	<-4.3> 3.7	<-6.1> 10.5
Hanp <treatment for acute cardiac failure>	<-7.8> 2.4	<-3.2> 1.8	<-5.2> 2.8	<-8.1> 2.2	<-6.2> 9.2	<-1.5> 2.4	<-11.3> 2.1	<-4.8> 2.6	<-1.6> 7.1
Livalo <antihyperlipidemic agent>	<-10.0> 1.5	<-13.8> 1.5	<-8.1> 1.8	<-16.6> 1.4	<-11.8> 6.1	<-22.8> 1.8	<-25.9> 1.8	<-18.8> 2.1	<-22.3> 5.7
Sunrythm <antiarrhythmic agent>	<-4.2> 3.1	<-2.9> 2.9	<-6.1> 3.2	<-0.3> 2.5	<-3.6> 11.6	<-1.2> 3.0	<-3.4> 3.0	<-0.8> 3.2	<-0.4> 9.2
Fastic <antidiabetic agent>	<-0.5> 1.3	<-0.1> 1.3	<-2.9> 1.4	<-1.3> 1.1	<-1.2> 5.1	<-1.8> 1.4	<-7.3> 1.4	<-0.1> 1.4	<-2.9> 4.1
<b>Infectious diseases / bone and joint diseases / immunological allergic diseases / urology</b>	<b>&lt;-8.3&gt;</b> <b>30.8</b>	<b>&lt;-4.2&gt;</b> <b>31.9</b>	<b>&lt;-2.6&gt;</b> <b>44.7</b>	<b>&lt;-4.6&gt;</b> <b>30.0</b>	<b>&lt;-1.0&gt;</b> <b>137.4</b>	<b>&lt;-9.4&gt;</b> <b>33.7</b>	<b>&lt;-16.4&gt;</b> <b>37.2</b>	<b>&lt;-0.2&gt;</b> <b>44.7</b>	<b>&lt;-7.6&gt;</b> <b>115.6</b>
Cravit <synthetic antibacterial agent>	<-15.5> 10.2	<-6.0> 9.4	<-11.5> 13.7	<-1.2> 9.7	<-9.2> 43.0	<-6.8> 9.5	<-26.7> 11.9	<-21.0> 10.8	<-3.2> 32.3
Loxonin <anti-inflammatory analgesic>	<-2.2> 8.4	<-28.3> 10.4	<-17.1> 11.5	<-12.3> 8.3	<-15.1> 38.7	<-33.0> 11.2	<-19.7> 12.5	<-16.0> 13.3	<-22.0> 37.0
Mobic <anti-inflammatory analgesic>	<-13.1> 2.4	<-16.7> 2.1	<-23.1> 2.2	<-18.3> 1.6	<-17.8> 8.4	<-17.5> 2.0	<-8.9> 2.0	<-10.6> 2.0	<-12.6> 5.9
Urief <treatment for dysuria>	<-59.7> 1.8	<-45.4> 1.8	<-25.9> 2.1	<-60.5> 2.2	<-46.0> 7.9	<-26.6> 2.2	<-26.1> 2.2	<-19.3> 2.6	<-23.7> 7.0
Zyrtec <antiallergic agent>	<-23.8> 2.0	<-16.1> 1.6	<-15.6> 2.2	<-4.8> 3.5	<-14.1> 9.3	<-18.4> 2.4	<-13.3> 1.8	<-8.8> 2.4	<-13.4> 6.6
<b>Contrast agents / cancer / gastric diseases</b>	<b>&lt;-22.2&gt;</b> <b>12.3</b>	<b>&lt;-13.6&gt;</b> <b>12.5</b>	<b>&lt;-19.0&gt;</b> <b>13.9</b>	<b>&lt;-13.6&gt;</b> <b>10.1</b>	<b>&lt;-17.5&gt;</b> <b>48.8</b>	<b>&lt;-2.9&gt;</b> <b>12.6</b>	<b>&lt;-1.7&gt;</b> <b>12.7</b>	<b>&lt;-8.7&gt;</b> <b>12.7</b>	<b>&lt;-1.6&gt;</b> <b>38.0</b>
Omnipaque <contrast agent>	<-11.3> 7.3	<-5.4> 7.3	<-13.2> 8.0	<-4.7> 5.7	<-9.1> 28.3	<-2.0> 7.1	<-3.4> 7.5	<-10.8> 7.1	<-3.4> 21.8
Topotecin <anticancer agent>	<-0.7> 1.6	<-2.1> 1.5	<-1.0> 1.7	<-2.1> 1.4	<-0.9> 6.2	<-5.6> 1.7	<-4.6> 1.6	<-14.2> 1.5	<-1.7> 4.8

### 7-2. Daiichi Sankyo Healthcare Co., Ltd

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
<b>Daiichi Sankyo Healthcare Co., Ltd</b>	<b>&lt;-3.1&gt;</b> <b>10.2</b>	<b>&lt;-5.2&gt;</b> <b>13.8</b>	<b>&lt;-13.2&gt;</b> <b>13.2</b>	<b>&lt;-6.5&gt;</b> <b>10.1</b>	<b>&lt;-6.2&gt;</b> <b>47.2</b>	<b>&lt;-6.9&gt;</b> <b>9.5</b>	<b>&lt;-2.1&gt;</b> <b>13.5</b>	<b>&lt;-8.2&gt;</b> <b>12.1</b>	<b>&lt;-5.6&gt;</b> <b>35.1</b>
LuLu Series	<-8.7> 1.2	<-2.0> 3.6	<-4.0> 3.5	<-6.9> 1.4	<-2.2> 9.8	<-2.4> 1.2	<-18.9> 4.3	<-19.5> 2.8	<-0.4> 8.3
Gaster 10	<-15.5> 0.7	<-7.8> 0.9	<-2.6> 1.0	<-12.6> 0.7	<-5.5> 3.3	<-29.1> 0.5	<-45.7> 0.5	<-38.9> 0.6	<-38.6> 1.6
Shin-Sankyo Ichoyaku series	<-7.9> 0.7	<-31.2> 0.9	<-26.4> 1.0	<-12.1> 0.7	<-5.2> 3.3	<-26.3> 0.9	<-1.1> 0.9	<-2.8> 1.0	<-7.7> 2.8
Patecs series	<-19.5> 0.8	<-9.0> 0.8	<-0.0> 0.7	<-9.3> 0.4	<-10.4> 2.7	<-15.3> 0.9	<-17.8> 0.6	<-25.9> 0.5	<-8.8> 2.1
Transino	<-> 0.7	<-62.0> 0.5	<-76.9> 0.2	<-69.6> 0.1	<-41.4> 1.5	<-62.3> 0.3	<-72.0> 0.2	<-37.4> 0.2	<-54.5> 0.6

## 7-3. Daiichi Sankyo, Inc. (US)

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Daiichi Sankyo, Inc. (DSI)	<12.0>	<-0.6>	<-13.5>	<-15.3>	<-1.9>	<-11.2>	<-5.6>	<-5.8>	<-0.5>
mil USD	37.2	31.7	32.6	27.9	129.3	33.0	33.5	34.4	100.9
	<29.4>	<-8.4>	<-2.1>	<-27.9>	<-15.8>	<-4.6>	<-21.7>	<-13.4>	<-9.4>
	356	294	337	300	1,286	339	357	382	1,079
Benicar / Benicar HCT <antihypertensive>	<2.6>	<-1.8>	<-7.5>	<-1.6>	<-0.6>	<-5.6>	<0.5>	<-2.0>	<-1.1>
mil USD	23.4	22.1	22.3	19.6	87.4	22.1	22.2	22.7	67.0
	<-18.6>	<-11.3>	<-8.7>	<-14.1>	<-13.0>	<-1.4>	<-15.6>	<-9.7>	<-8.7>
	223	205	230	210	869	227	237	253	716
Azor <antihypertensive>	<->	<->	<-39.6>	<-241.8>	<-240.7>	<-121.5>	<-30.9>	<-38.6>	<-53.4>
mil USD	1.4	2.4	2.6	2.3	8.7	3.0	3.2	3.6	9.8
	<->	<->	<-66.2>	<-285.1>	<-287.2>	<-138.0>	<-49.3>	<-50.9>	<-68.6>
	13	23	27	24	86	31	34	40	105
Welchol <antihyperlipidemic / type 2 diabetes>	<-11.0>	<-8.8>	<-6.6>	<-4.3>	<-7.8>	<-7.0>	<-6.6>	<-10.2>	<-8.0>
mil USD	6.4	6.1	6.6	5.3	24.5	6.9	6.5	7.3	20.7
	<-28.2>	<-18.9>	<-24.7>	<-17.8>	<-22.5>	<-14.9>	<-22.8>	<-18.7>	<-18.7>
	62	57	68	57	244	71	69	81	221
Effient (alliance revenue) <antiplatelet>						<->	<->	<->	<->
mil USD	-	-	-	-	-	-	1.0	0.2	1.1
	-	-	-	-	-	-	<->	<->	<->
	-	-	-	-	-	-	10	2	12

## 7-4. Luitpold Pharmaceuticals, Inc. (US)

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Luitpold Pharmaceuticals, Inc. (LPI)	<-13.8>	<-6.4>	<-0.5>	<-17.8>	<-0.1>	<-1.1>	<-0.4>	<-6.4>	<-2.6>
mil USD	13.5	13.5	13.4	10.7	51.1	13.4	13.5	12.6	39.4
	<-31.4>	<-16.5>	<-16.9>	<-5.7>	<-13.8>	<-6.2>	<-14.5>	<-1.1>	<-7.0>
	129	126	139	115	509	137	144	140	421
Venofor <treatment for iron deficiency anemia>	<-23.1>	<-6.4>	<-1.7>	<-15.3>	<-3.1>	<-3.9>	<-4.6>	<-4.1>	<-4.2>
mil USD	8.3	8.5	8.3	6.9	32.0	8.0	8.1	8.0	24.1
	<-42.2>	<-16.7>	<-19.5>	<-2.8>	<-17.2>	<-3.2>	<-9.6>	<-3.3>	<-5.3>
	80	79	86	74	319	82	87	89	258

## 7-5. Daiichi Sankyo Europe GmbH

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
Daiichi Sankyo Europe GmbH (DSE)	<-53.1>	<-42.4>	<-24.2>	<-2.4>	<-9.9>	<-14.1>	<-0.4>	<-6.1>	<-6.1>
mil €	15.2	18.5	18.0	18.6	70.3	17.3	18.4	19.1	54.8
	<-54.2>	<-42.5>	<-53.8>	<-27.9>	<-0.8>	<-40.6>	<-20.8>	<-5.9>	<-20.2>
	93	114	136	147	490	131	138	144	412
Olmotec / Olmetec Plus <antihypertensive>	<-44.3>	<-40.7>	<-10.1>	<-13.6>	<-10.3>	<-0.2>	<-3.7>	<-12.1>	<-2.5>
mil €	8.3	10.3	9.1	9.7	37.5	8.3	10.0	10.2	28.5
	<-45.6>	<-40.5>	<-37.5>	<-8.5>	<-0.3>	<-23.0>	<-16.7>	<-10.6>	<-16.2>
	51	64	70	77	261	63	74	77	214
Sevikar <antihypertensive>	-	-	<->	<->	<->	<->	<->	<-56.5>	<-208.1>
mil €	-	-	1.4	0.8	2.2	0.9	1.2	2.2	4.3
	-	-	<->	<->	<->	<->	<->	<-77.6>	<-249.2>
	-	-	9	6	15	7	9	16	32
Mevalotin <antihyperlipidemic agent>	<-74.3>	<-3.4>	<-1.2>	<-43.9>	<-40.7>	<-11.3>	<-34.0>	<-37.7>	<-25.2>
mil €	0.7	1.2	1.2	0.7	4.0	0.8	0.8	0.8	2.4
	<-74.9>	<-3.6>	<-23.3>	<-25.7>	<-33.7>	<-37.2>	<-20.0>	<-36.7>	<-15.2>
	4	8	9	6	28	6	6	6	18
Evista <treatment for osteoporosis>	<-71.7>	<-419.7>	<-134.5>	<-57.8>	<-128.5>	<-24.9>	<-27.5>	<-31.1>	<-27.8>
mil €	3.2	3.5	3.0	2.2	12.0	2.4	2.6	2.1	7.1
	<-67.7>	<-421.3>	<-195.4>	<-111.8>	<-155.6>	<-7.5>	<-12.2>	<-32.8>	<-18.2>
	20	22	23	18	84	18	19	16	53

\* Following the change in fiscal year-end, FY2007 results for DSE, Olmetec / Olmetec Plus, Mevalotin and Evista are fifteen-months totals from Jan-07 to Mar-08.

Three months results from Jan-07 to Mar-07 were ¥14.1 billion (€9 million), ¥6.4 billion (€40 million), ¥1.6 billion (€10 million), and ¥1.0 billion (€6 million), respectively.

## Alliance Revenue of Effient (Europe)

Effient <antiplatelet>				<->	<->	<->	<->	<->	<->
mil USD	-	-	-	0.03	0.03	0.0	0.0	0.1	0.1
	-	-	-	<->	<->	<->	<->	<->	<->
	-	-	-	0.3	0.3	0	0	1	1

\* Alliance Revenue of Effient (Europe) is booked on Daiichi Sankyo Co., Ltd., thus, total sales of DSE above does not include Alliance Revenue of Effient (Europe).

## 7-6. Asia, South and Central America (ASCA)

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
<b>ASCA Total</b>	<b>&lt;10.5&gt;</b> <b>5.2</b>	<b>&lt;12.7&gt;</b> <b>5.8</b>	<b>&lt;14.3&gt;</b> <b>5.9</b>	<b>&lt;1.6&gt;</b> <b>6.0</b>	<b>&lt;9.5&gt;</b> <b>23.0</b>	<b>&lt;0.5&gt;</b> <b>5.3</b>	<b>&lt;7.1&gt;</b> <b>6.3</b>	<b>&lt;11.7&gt;</b> <b>6.6</b>	<b>&lt;6.6&gt;</b> <b>18.1</b>
Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. (DSBJ)	<10.9> 1.0	<0.8> 1.0	<11.4> 1.1	<22.0> 0.9	<1.3> 4.0	<4.3> 1.0	<7.6> 1.1	<3.1> 1.1	<2.2> 3.2
Daiichi Sankyo Pharmaceutical(Shanghai) Co., Ltd. (DSSH)	<29.5> 0.7	<64.3> 0.9	<62.4> 1.1	<126.2> 1.1	<69.0> 3.8	<48.0> 1.1	<40.2> 1.3	<35.2> 1.4	<40.3> 3.8
Daiichi Sankyo Korea Co., Ltd. (DSKR)	<4.3> 0.9	<1.1> 0.9	<35.5> 0.6	<19.7> 0.6	<12.4> 3.0	<15.6> 0.8	<2.1> 0.9	<56.8> 0.9	<7.1> 2.5
Daiichi Sankyo (Thailand) Ltd. (DSTH)	<4.9> 0.2	<17.9> 0.2	<3.3> 0.2	<13.4> 0.2	<1.4> 0.8	<0.9> 0.2	<0.4> 0.2	<4.2> 0.2	<1.0> 0.6
Daiichi Sankyo Taiwan Ltd. (DSTW)	<1.6> 0.9	<1.2> 1.0	<9.0> 0.8	<15.5> 0.8	<5.4> 3.5	<8.6> 0.9	<14.9> 0.8	<14.4> 0.7	<12.5> 2.4
Daiichi Sankyo Brasil Farmacêutica Ltda. (DSBR)	<11.5> 1.0	<14.9> 1.2	<38.7> 1.4	<4.2> 1.4	<13.6> 5.0	<25.5> 0.8	<12.7> 1.0	<7.2> 1.3	<14.1> 3.1
Daiichi Sankyo Venezuela, S.A. (DSVE)	<21.7> 0.5	<12.0> 0.6	<40.5> 0.7	<9.8> 1.0	<19.0> 2.8	<35.3> 0.7	<45.0> 0.9	<20.7> 0.8	<32.9> 2.4

## 7-7. Ranbaxy Laboratories Limited

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
<b>Ranbaxy Laboratories Limited</b>	-	-	-	<>	<>	<>	<>	<>	<>
<b>bil INR</b>	-	-	-	<>	<>	15.7	18.2	18.5	52.4
				38.6	38.6	29.7	36.4	36.0	102.2

## 7-8. ASCA &amp; Ranbaxy's Sales of Global Products

(Billions of yen)

	FY2008					FY2009			
	Q1	Q2	Q3	Q4	Full Year	Q1	Q2	Q3	Q3 YTD
<b>Olmesartan</b> <antihypertensive>	<69.3> 1.3	<110.1> 1.9	<98.0> 2.1	<38.4> 2.1	<74.2> 7.3	<42.4> 1.8	<25.7> 2.4	<22.7> 2.5	<28.6> 6.8
<b>Levofloxacin</b> <synthetic antibacterial>	<1.8> 1.9	<0.9> 1.9	<11.9> 1.8	<2.6> 1.8	<4.0> 7.5	<6.4> 1.8	<2.9> 2.0	<14.7> 2.1	<3.6> 5.9
<b>Pravastatin</b> <antihyperlipidemic>	<3.1> 0.8	<7.6> 0.8	<25.4> 0.6	<7.1> 0.9	<7.2> 3.0	<7.7> 0.8	<8.4> 0.8	<37.8> 0.8	<16.4> 2.5



(This page is intentionally left blank)



**DAIICHI SANKYO CO., LTD.**



DAIICHI SANKYO CO., LTD.